Key clinical point: A higher dose of onabotulinumtoxinA (Botox ®) may decrease the number of headache and severe headache days in patients with chronic migraine who had an unsatisfactory response to the conventional 150-unit dose.
Major finding: After receiving 3 rounds of 200 units onabotulinumtoxinA, patients had a significant reduction in headache (13.62 ± 10.79 to 11.02 ± 10.61) and severe headache (5.88 ± 6.73 to 4.01 ± 4.89) days (both P < .001).
Study details: This retrospective paired comparison study included 175 patients with chronic migraine who received ≥3 rounds of 150 units onabotulinumtoxinA followed by ≥3 rounds of 200 units onabotulinumtoxinA.
Disclosures: This study did not receive any funding. The authors declared no conflicts of interest.
Source: Zandieh A, Cutrer FM. OnabotulinumtoxinA in chronic migraine: Is the response dose dependent? BMC Neurol. 2022;22:218 (Jun 13). Doi: 10.1186/s12883-022-02742-x